🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Rhythm Pharma's setmelanotide shows positive action in rare obesity disorders; investors unmoved, shares down 9%

Published 06/18/2018, 01:03 PM
© Reuters.  Rhythm Pharma's setmelanotide shows positive action in rare obesity disorders; investors unmoved, shares down 9%
RYTM
-
  • Thinly traded Rhythm Pharmaceuticals (RYTM -8.7%) is down on below average volume on the heels of its announcement of new data from basket studies of MC4R receptor agonist setmelanotide in patients with rare inherited obesity disorders.
  • Four patients with Bardet-Biedl Syndrome (BBS) treated with setmelanotide experienced an average weight loss of 18.5% with an average decrease on hunger score of 74.2%.
  • The first patient with Alström Syndrome (AS) experienced a 23.2% loss in weight and 45.5% decrease in hunger score.
  • Two patients with pro-opiomelanocortin (POMC) and other MC4 pathway heterozygous deficiency obesities experienced weight losses of 15.4% and 6.5%, respectively, during treatment.
  • A combined study in BBS and AS should launch by year-end.
  • Now read: ContraFect: A Buy For Their Next Generation Anti-Infection Proteins


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.